Online inquiry

IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12143MR)

This product GTTS-WQ12143MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD248 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_020404.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57124
UniProt ID Q9HCU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12143MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8984MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ3419MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ2421MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ15863MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ5760MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ9109MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ4297MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ13787MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW